This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Comparison of trace elements in peripheral blood and bone marrow of newly diagnosed multiple myeloma patients
Clinical and Experimental Medicine Open Access 17 April 2024
-
Targeting ferroptosis for leukemia therapy: exploring novel strategies from its mechanisms and role in leukemia based on nanotechnology
European Journal of Medical Research Open Access 09 April 2024
-
The modulation of iron metabolism affects the Rhabdomyosarcoma tumor growth in vitro and in vivo
Clinical and Experimental Medicine Open Access 10 February 2023
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Gozzelino R, Arosio P . Iron homeostasis in health and disease. Int J Mol Sci 2016; 17 : E130.
Hentze MW, Muckenthaler MU, Galy B, Camaschella C . Two to tango: regulation of Mammalian iron metabolism. Cell 2010; 142 : 24–38.
Tu BP, Weissman JS . Oxidative protein folding in eukaryotes: mechanisms and consequences. J Cell Biol 2004; 164 : 341–346.
Shimizu Y, Hendershot LM . Oxidative folding: cellular strategies for dealing with the resultant equimolar production of reactive oxygen species. Antioxid Redox Signal 2009; 11 : 2317–2331.
Bordini J, Bertilaccio MT, Ponzoni M, Fermo I, Chesi M, Bergsagel PL et al. Erythroblast apoptosis and microenvironmental iron restriction trigger anemia in the VK*MYC model of multiple myeloma. Haematologica 2015; 100 : 834–841.
Gu Z, Wang H, Xia J, Yang Y, Jin Z, Xu H et al. Decreased ferroportin promotes myeloma cell growth and osteoclast differentiation. Cancer Res 2015; 75 : 2211–2221.
Wu KJ, Polack A, Dalla-Favera R . Coordinated regulation of iron-controlling genes, H-ferritin and IRP2, by c-MYC. Science 1999; 283 : 676–679.
Affer M, Chesi M, Chen WD, Keats JJ, Demchenko YN, Tamizhmani K et al. Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma. Leukemia 2014; 28 : 1725–1735.
Chesi M, Robbiani DF, Sebag M, Chng WJ, Affer M, Tiedemann R et al. AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell 2008; 13 : 167–180.
Campanella A, Santambrogio P, Fontana F, Frenquelli M, Cenci S, Marcatti M et al. Iron increases the susceptibility of multiple myeloma cells to bortezomib. Haematologica 2013; 98 : 971–979.
Kamihara Y, Takada K, Sato T, Kawano Y, Murase K, Arihara Y et al. The iron chelator deferasirox induces apoptosis by targeting oncogenic Pyk2/beta-catenin signaling in human multiple myeloma. Oncotarget 2016; e-pub ahead of print 2 September 2016 doi:10.18632/oncotarget.11830.
Klein B, Zhang XG, Lu ZY, Bataille R . Interleukin-6 in human multiple myeloma. Blood 1995; 85 : 863–872.
Steinmetz T, Tschechne B, Harlin O, Klement B, Franzem M, Wamhoff J et al. Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. Ann Oncol 2013; 24 : 475–482.
Hedenus M, Karlsson T, Ludwig H, Rzychon B, Felder M, Roubert B et al. Intravenous iron alone resolves anemia in patients with functional iron deficiency and lymphoid malignancies undergoing chemotherapy. Med Oncol 2014; 31 : 302.
Toledano A, Luporsi E, Morere JF, Scotte F, Laribi K, Barriere J et al. Clinical use of ferric carboxymaltose in patients with solid tumours or haematological malignancies in France. Support Care Cancer 2016; 24 : 67–75.
Acknowledgements
We thank Giovanni Tonon for the valuable advice. This work was supported by AIRC-Fondazione Cariplo TRIDEO 2014 no. 15465 (to AC) and by AIRC Program Grant in Molecular Oncology-Extension no. 9965 (to AC).
Author contributions
JB performed research, analyzed results and contributed to writing the paper. SG and MTSB performed research. MP performed research and contributed to writing the paper. MC and PLB provided the Vk*MYC model, analyzed the data and contributed to writing the paper. CC contributed to the experimental design and to writing the paper. AC designed the experimental work, performed research and wrote the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Bordini, J., Galvan, S., Ponzoni, M. et al. Induction of iron excess restricts malignant plasma cells expansion and potentiates bortezomib effect in models of multiple myeloma. Leukemia 31, 967–970 (2017). https://doi.org/10.1038/leu.2016.346
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2016.346
This article is cited by
-
Targeting ferroptosis for leukemia therapy: exploring novel strategies from its mechanisms and role in leukemia based on nanotechnology
European Journal of Medical Research (2024)
-
Unlocking ferroptosis in prostate cancer — the road to novel therapies and imaging markers
Nature Reviews Urology (2024)
-
Comparison of trace elements in peripheral blood and bone marrow of newly diagnosed multiple myeloma patients
Clinical and Experimental Medicine (2024)
-
The modulation of iron metabolism affects the Rhabdomyosarcoma tumor growth in vitro and in vivo
Clinical and Experimental Medicine (2023)